SAN FRANCISCO, CA USA (UroToday.com) - Dr. Abdenour Nabid and colleagues from Québec City, Canada reported on long-term quality of life (QOL) in 630 patients with high-risk prostate cancer (HRPC) treated in a prospective randomized phase III trial.
For this trial, Patients were randomized to radiotherapy (RT) plus 36 or 18 months of androgen deprivation therapy (ADT). They assessed QOL by two validated tools: EORTC30 (30 items) and PR25 (25 items). The 55 items were regrouped into 21 scales: 15 for EORTC30 and 6 for PR25. A p value less than 0.01 was considered statistically significant and a difference between groups in mean scores of greater than or equal to 10 points as clinically relevant. Patient-reported outcomes were filled out before treatments, every 6 months during ADT, 4 months after, and then once-a-year for 5 years.
The global adherence to QOL questionnaires was about 72% (10 052 out of 13 880). Three-hundred ten patients were randomized to 36 months and 320 to 18 months of ADT. With a median follow-up of 79 months, no difference in survival outcomes was reported. Comparing the 2 groups, patients on 18-months of ADT significantly reported better QOL (p < 0.01). None of the 21 scales reached clinical relevance, sexually active being the highest score with 9.0 points of difference. For the 14 statistically significant items, interest in sex with 9.9 points and sexually active with 8.1 points were close to clinical relevance, and hot flushes with 24 points and enjoyable sex with 18 points had important clinical relevance at 42 months.
The conclusion of their study was that in HRPC treated with RT and ADT, reducing the duration of ADT from 36 to 18 months improves QOL, without a negative impact on survival.
Click HERE to read the abstract for this session
Highlights of a presentation by Abdenour Nabid, MD at the 2014 Genitourinary Cancers Symposium - January 30 - February 1, 2014 - San Francisco Marriott Marquis - San Francisco, California USA
Centre Hospitalier de Universitaire de Sherbrooke in Sherbrooke, Quebec Canada
Written by Reza Mehrazin, MD, medical writer for UroToday.com
View Full 2014 GU Cancers Symposium Coverage